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Summary
Using a novel approach that detects changes in the conformation of ER, we studied the efficacy of anti-estrogens to
inactivate ER under different experimental conditions. We show that phosphorylation of serine-305 in the hinge region
of ER by protein kinase A (PKA) induced resistance to tamoxifen. Tamoxifen bound but then failed to induce the inactive
conformation, invoking ER-dependent transactivation instead. PKA activity thus induces a switch from antagonistic to
agonistic effects of tamoxifen on ER. In clinical samples, we found that downregulation of a negative regulator of PKA,
PKA-RI, was associated with tamoxifen resistance prior to treatment. Activation of PKA by downregulation of PKA-RI
converts tamoxifen from an ER inhibitor into a growth stimulator, without any effect on ICI 182780 (Fulvestrant).
Introduction Understanding the mechanism of tamoxifen resistance in ER
breast cancers should allow early identification of these tumors
Approximately 70% of all breast cancers are dependent for their and adaptation of the treatment before more aggressive cells
growth on estrogen and on a functional estrogen receptor  arise.
(ER). Hence, ER-positive breast cancer is usually treated with ER is a member of the nuclear hormone receptor superfam-
hormone reduction or anti-estrogens (Ali and Coombes, 2002). ily and regulates transcription of ER-specific target genes in
The most commonly used anti-estrogen is tamoxifen, and it has response to the hormone estradiol (E2) (Mangelsdorf et al.,
been calculated that about one million years of life are saved 1995). ER contains several functional domains, including a
by tamoxifen per year in the developed countries (Forbes, 1997). centrally located DNA binding domain connected through a
Still, only half of the recurrences in ER breast tumors respond hinge region to a C-terminal ligand binding domain (LBD) that
to tamoxifen, while the other half show resistance. Mutations binds the agonist estradiol, but also antagonists such as tamoxi-
in ER that lead to resistance are rarely found in patients (Hopp fen and ICI-182780 (commercial name: Faslodex or Fulvestrant).
and Fuqua, 1998), whereas multiple other mechanisms have Hormone binding results in rapid dissociation from chaperone
been associated with tamoxifen resistance in vitro. Reported proteins, leading to binding of an ER homodimer to its cognate
are: phosphorylation of the ER by protein kinase A (PKA) (Le- estrogen responsive element (ERE) binding site on the DNA.
Goff et al., 1994) or MAP-kinase (Kato et al., 1995), overexpres- This initiates transcription by recruiting the basal transcription
sion of c-erbB2 (Pietras et al., 1995), EGF-R or SRC-1 (Shang machinery through a variety of coactivators, including steroid
and Brown, 2002), and stabilization of the interaction between receptor cofactor-1 (SRC-1) and AIBI (Smith et al., 1996). It is
ER and SRC-1 by cyclin D1 (Zwijsen et al., 1997) and cyclin this recruitment that is inhibited by anti-estrogens.
A-CDK2 (Trowbridge et al., 1997). Whether these mechanisms The conformation of the LBD of ER is affected by ligand
binding (Kraus et al., 1995; Shiau et al., 1998; Norris et al., 1999;are operational in tamoxifen-resistant breast cancer is unclear.
S I G N I F I C A N C E
Estrogen receptor-positive breast cancer patients are commonly treated with the anti-estrogen tamoxifen, which gives a 50%
reduction in recurrence. Here, we describe that inactivation of the estrogen receptor by anti-estrogens leads to rapid conformational
changes in the receptor, which can be followed by FRET (fluorescence resonance energy transfer). Using this method, we can
determine the efficacy of two different anti-estrogens, tamoxifen and Fulvestrant. Breast cancers resistant to tamoxifen are often still
sensitive to Fulvestrant. We demonstrate that resistance to tamoxifen is mediated by a modification of the estrogen receptor by
protein kinase A, not only in experimental setting, but in breast cancer patients as well. This modification converts the antagonist
tamoxifen into an agonist, reversing its effect on tumor cell growth.
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Figure 1. Characterization of YFP-ER-CFP-
expressing U2OS cells
A: Scheme of the fusion protein of ER with YFP
at the N terminus and CFP at the C terminus.
B: Distribution of YFP-ER-CFP in transiently trans-
fected U2OS cells. Confocal microscopy showed
cells with YFP-positive nuclei.
C: Western blot analysis. A 119 kDa fusion protein
of YFP-ER-CFP was detected by antibodies to
GFP and ER in transfected U2OS cells. The 67 kDa
wt-ERwas detected by anti-ER antibody in T47D
breast cancer cells.
D: ERE-dependent luciferase activity in the pres-
ence of medium with 5% CTS (charcoal treated
serum), 107 M E2, 107 M 4-OH-tamoxifen (TAM),
or 107 M ICI-182780 (ICI).
E: ERE-dependent luciferase activity of T47D
breast cancer cells containing wt ER and U2OS
cells containing YFP-ER-CFP in the presence of
various concentrations of E2.
F and G: ERE-dependent luciferase activity of
T47D breast cancer cells containing wt ER and
U2OS cells containing YFP-ER-CFP in the pres-
ence of 108 ME2 (T47D cells) or 3  109 ME2
(U2OS containing YFP-ER-CFP cells) in the pres-
ence of various concentrations of OH-tamoxifen
(F) or ICI-182780 (G).
Metivier et al., 2002). Estradiol binding affects the conformation detected by Western blot analysis with anti-ER and anti-GFP
antibodies (Figure 1C). This construct was normally able to in-of helix12 of the LBD such that coactivators are recruited and
transcription ensues. Anti-estrogens like tamoxifen and ICI- duce ERE-mediated transactivation. Culturing the cells with es-
tradiol for 48 hr resulted in a 35-fold increase of ERE-luciferase182780 bind to the same site (Pike et al., 2001), but induce
a reorientation of this particular helix, thereby preventing the activity over control cells grown in estrogen-depleted serum
(CTS), whereas tamoxifen or ICI-182780 hardly induced ERE-interaction with coactivators and inhibiting ER-driven transcrip-
tion. Yet, the effects of the individual anti-estrogens are not mediated reporter activity (Figure 1D). These values were com-
parable to those found using a nonmodified pCMV-ER constructidentical (Park and Jordan, 2002; Osborne et al., 1995, 2000).
For example, a fraction of ER-positive tamoxifen resistant breast (data not shown), indicating that the GFP modifications did not
alter the activity of ER. Moreover, the pCMV-ER wt and thetumors is still sensitive to ICI-182780 in vitro as well as in vivo
in patients (Osborne et al., 1995, 2002; Howell et al., 1995, YFP-ER-CFP fusion construct showed comparable IC50 and
EC50 values for estradiol, OH-tamoxifen, and ICI-182780 in2002). The fact that estrogen and anti-estrogens induce different
ER conformations was the rationale behind designing a fluores- transactivation assays (Figures 1E–1G).
Subsequently, we measured conformational changes in ERcence resonance energy transfer (FRET) probe that can monitor
these conformations in living cells (Zhang et al., 2002). by FRET after addition of estradiol (E2) or the anti-estrogens
tamoxifen and ICI-182780. Alterations in the distance or orienta-
tion of CFP and YFP will potentially affect energy transfer fromResults
CFP to YFP, which can be observed when CFP is excited at
432 nm and the emission of CFP (at 478 nm) and YFP (at 527FRET marks inactivation of ER
We generated a recombinant ERwith two variants of the green nm) is simultaneously measured (Figure 2A). In case of energy
transfer, emission of YFP should occur at the expense of CFPfluorescent protein: YFP at the N- and CFP at the C terminus
(Figure 1A). Any alteration in position or orientation of the CFP (Zhang et al., 2002), and alterations in FRET (fluorescence reso-
nance energy transfer) are depicted as changes in ratio betweenand YFP molecules may result in a change in energy transfer
between these fluorophores (Zhang et al., 2002; van der Wal et these two signals. Living U2OS cells transfected with the YFP-
ER-CFP construct were assayed in the presence of variousal., 2001). First, we determined whether the YFP/CFP modifica-
tion affects the normal behavior of ER. U2OS cells stably trans- combinations of estrogen (E2), tamoxifen, and ICI-182780 (as
indicated in Figures 2B–2D). An alteration in FRET was observedfected with the YFP-ER-CFP construct showed fluorescent nuclei
(Figure 1B) containing a 119 kDa YFP-ER-CFP fusion protein, as only after addition of tamoxifen or ICI-182780, and reached
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Figure 3. Manipulation of tamoxifen-induced inactivation of ER
A: FRET values (shown as maximal percentage alteration in FRET ratio) in
YFP-ER-CFP-expressing U2OS cells after addition of 107 M 4-OH-tamoxifen
or 107 M ICI-182780 to control cells (/), cells expressing either cyclin D1
or SRC-1, cells pretreated with 8Br-cAMP (cAMP), or cells containing various
combinations as indicated. Bars indicate the standard error in at least four
independent experiments.
B: ER transcriptional activity measured by ERE-dependent luciferase assay
under the same conditions as in A. Cells were cultured for two days in the
presence of either CTS medium, 107 M 4-OH-tamoxifen (TAM), or 107 M
ICI-182780 (ICI) and subsequently assayed by the ERE-luciferase assay as
described in Experimental Procedures. Bars indicate standard error in tripli-
cate experiments.
completion within 10 min. E2 did not affect FRET, not even
when a 10-fold molar excess was added after anti-estrogen
addition (Figure 2C). Apparently, the YFP-ER-CFP FRET probe
only detected ER inactivation by the anti-estrogens tamoxifen
or ICI-182780, and not activation by E2. Application of the FRET
in physiologically more relevant MCF7 and T47D breast cancer
cells yielded similar FRET alterations upon addition of OH-
tamoxifen and ICI-182780. Since U2OS cells are more easily
transfected, and since we wanted to study initial conformational
changes in YFP-ER-CFP in cells devoid of endogenous ER,
U2OS cells were used in further FRET studies.
Since ER forms homodimers, the FRET changes observed
could result from inter- or intramolecular energy transfer be-
tween CFP and YFP. To investigate this, we examined the FRET
Figure 2. Visualization of ER inactivation by anti-estrogens using FRET
changes in U2OS cells that were transfected with either YFP-
A: Principle of FRET. Exciting CFP at 432 nm results in emission at 478 nm ER or ER-CFP alone or with equal amounts of both constructsunless energy is transferred to YFP. An increased YFP (at 527 nm) at the
(Figure 2E). No detectable FRET changes occurred upon tamox-expense of CFP emission can occur as the result of a conformational
change of ER. ifen addition in cells with either YFP-ER or ER-CFP expression
B: FRET change induced by tamoxifen. Time course of emission of YFP (yel- alone, nor in cells expressing both constructs. These findings
low) and CFP (blue) and corresponding ratio of YFP/CFP emission (red) of indicated that ER inactivation by anti-estrogens (Figure 2) re-one YFP-ER-CFP-containing U2OS cell after subsequent addition of 107 M
sulted in an intramolecular change in ER that can be visualizedestradiol (E2) and 106 M 4-OH-tamoxifen (TAM), as indicated.
C: Time course of YFP/CFP emission ratio of one YFP-ER-CFP-containing U2OS by FRET.
cell after subsequent addition of 107 M 4-OH-tamoxifen (TAM) (left) or 107
M ICI-182780 (ICI) (right) followed by addition of 106 M estradiol (E2), as Resistance to anti-estrogens measured by FRETindicated.
The FRET probe was used for assaying conditions that induceD: Time course of YFP/CFP emission ratio of one YFP-ER-CFP-containing U2OS
cell cultured in the presence of 107 M 4-OH-tamoxifen (TAM) and 106 M resistance to the anti-estrogens tamoxifen or ICI-182780 (Figure
ICI-182780 (ICI), as indicated (left), or with the same compounds in the 3A). Depicted is the maximal alteration in FRET ratio, as shown
reversed order (right). in Figure 2. We tested various factors associated with ligand-E: FRET detects an intramolecular change in ER. Time course of YFP/CFP
independent transactivation of ER, including SRC-1 (steroid re-emission ratio of one U2OS cells expressing YFP-ER (left), ER-CFP (middle),
or both YFP-ER and ER-CFP (right). The cells were cultured in CTS-containing ceptor cofactor-1) (Shang and Brown et al., 2002), cyclin D1
medium followed by addition of 107 M 4-OH-tamoxifen (TAM). (Zwijsen et al., 1997), and cAMP (LeGoff et al., 1994). As indi-
cated in Figure 3A, membrane-permeable 8-Br-cAMP (Hordijk
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et al., 1994) prevented tamoxifen-associated FRET changes
in YFP-ER-CFP transfected U2OS cells, whereas 8-Br-cAMP
in combination with cyclin D1 and SRC-1 was required to
overcome the ICI-182780-induced FRET change. Without
8-Br-cAMP, overexpression of cyclin D1 and SRC-1, either
alone or in combination, was not sufficient to overcome the
tamoxifen or ICI-182780-induced FRET change. ERE-depen-
dent luciferase assays in U2OS cells were used to confirm that
the changes in FRET were associated with inhibition of ER and
subsequent reduction of ER transactivation, whereas resistance
to anti-estrogens was associated with no alteration in FRET and
with ER transactivation in the presence of anti-estrogens (Figure
3B). Administration of 8-Br-cAMP resulted in a 5.5-fold increase
of the basal activity of the reporter construct under CTS condi-
tions alone (Figure 3B) that is not accompanied by a FRET
change. Only anti-estrogens induce a conformational change
that results in a FRET alteration.
Next, we applied FRET to investigate the mechanism of
resistance toward anti-estrogens induced by 8-Br-cAMP. This
compound overcomes the tamoxifen- but not ICI-182780-
induced inactivation of ER, a situation often observed with ta-
moxifen-resistant patients as well (Howell et al., 1995; Osborne
et al., 2002). cAMP is generated by adenylate cyclase activity,
which can be stabilized by forskolin, and activates protein kinase
A (PKA). When added to the YFP-ER-CFP transfected U2OS
cells 15 min before anti-estrogen administration, forskolin pre-
vented tamoxifen-, but not the ICI-182780-induced, FRET
change (Figures 4B and 4C). Again, these findings were con-
firmed in ER-mediated transactivation experiments in the pres-
ence of 8Br-cAMP (Figure 3B). Surprisingly, addition of a 10-
fold molar excess of ICI-182780 after tamoxifen treatment did
not result in a FRET change (Figure 4B). The estrogen binding
site in ER was apparently occupied by tamoxifen, thus pre-
venting an ICI-182780-induced FRET change. The reverse was
also true: tamoxifen could not alter the ICI-induced conforma-
tional change as visualized by FRET (Figure 4C). Since ICI-
182780 substitution for tamoxifen was not observed in our ex-
periments (up to 120 min), this indicated that anti-estrogens
had a very low off-rate after ER binding. After PKA activation,
tamoxifen failed to induce the inactive state of ER, as measured
by FRET (Figure 4B), but instead induced ER-dependent tran-
Figure 4. Forskolin treatment selectively prevents tamoxifen-induced inacti-scription, as also visualized by the transactivation experiments
vation of ER
(Figure 3B). PKA activation thus converted tamoxifen from an
A–D: Time course of YFP/CFP ratio of a YFP-ER-CFP-expressing U2OS cellantagonist into an agonist.
cultured either in CTS medium (top) or treated with 105 M forskolin for 15
There are two consensus PKA phosphorylation sites in ER, min prior to FRET measurement (B–D). Subsequently, 107 M 4-OH-tamoxifen
(TAM) and 106 M ICI-182780 (ICI) (B) or in the reversed order (107 M ICIone within the DNA binding domain (serine-236) and a second
and 106 M TAM) (C) was added, as indicated. The right panel shows theat the N-terminal boundary of the ligand binding E domain, near
molecular interpretation of the FRET experiments. D: Phosphorylation of ser-the hinge region (serine-305) (Chen et al., 1999). Mutation of
ine-305 by PKA renders ER resistant to tamoxifen. Time course of YFP/CFP
serine-236 to alanine had a partial effect (data not shown). Muta- ratio of an YFP-ER(305A)-CFP expressing U2OS cell cultured in CTS and
tion of serine-305 to alanine, however, completely prevented treated with 105 M forskolin for 15 min prior to FRET measurement. Subse-
quently, 106 M 4-OH-tamoxifen (TAM) was added.the effect of forskolin on the tamoxifen induced, but not on the
E: In vitro phosphorylation of serine 305 by PKA. Equal amounts of proteinICI-182780-induced FRET change (Figure 4D). Serine 305 of
of wt and Ser→Ala 236 and/or -305 mutants of GFP-immunopurified YFP-
ER also appeared to be a bona fide target of PKA activity in ER-CFP were incubated with protein kinase A and 32P-ATP, and the reac-
an in vitro kinase assay (Figure 4E). The ER ser→ala 236 mutant tions were evaluated by autoradiography after gelectrophoresis and West-
ern blotting using antibody against GFP as described in the Experimentalprotein was efficiently phosphorylated, whereas the ser→ala
Procedures. Total U2OS protein was used as control.305 was not, indicating that not the ser-236 but rather the ser-
305 site in ER is the main target of PKA activity. We performed
these kinase experiments in vitro to exclude activation/involve-
ment of other kinases. PKA thus rendered ER resistant to
tamoxifen by phosphorylation of serine-305 in the hinge region.
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associated with tamoxifen resistance, which is consistent withTable 1. Reduced expression of PKA-RI is associated with tamoxifen
resistance our FRET data that PKA activation alone (by cAMP) renders
ER resistant to tamoxifen. To substantiate the relevance ofGene Nonrecurrenta Recurrentb p valuec
reduced expression of PKA-RI, we downregulated PKA-RI
Protein kinase A (PKA)-catalytic subunits
in the YFP-ER-CFP cells in our experimental system by RNAi
1 PRKAA1 0.009 0.108 0.191 (Figure 5A, insert). FRET analysis of U2OS cells cotransfected
 PRKACB 0.363 0.242 0.454 with the PKA-RI RNAi construct showed no alteration in FRET
 PRKACG 0.149 0.202 0.267
upon tamoxifen treatment, whereas ICI-182780 did induce a
Protein kinase A (PKA)-noncatalytic, AMP-activated subunits FRET change (Figure 5A). Again, addition of a ten-fold molar
1 PRKAB1 0.025 0.150 0.141 excess of ICI-182780 after tamoxifen treatment did not yield a
2 PRKAB2 0.006 0.004 0.974 FRET change, whereas addition of these compounds in the
1 PRKAG1 0.007 0.101 0.403 reverse order did show the regular ICI-182780-associated FRET
2 PRKAG2 0.024 0.056 0.490
alteration. Tamoxifen resistance of ER after PKA activation—
Protein kinase A (PKA)-noncatalytic, cAMP-dependent, regulatory through downregulation of PKA-RI—was confirmed in tradi-
subunits
tional ER-dependent transactivation assays that were per-
type I, 1 PRKAR1A 0.102 0.469 0.000 formed in U2OS cells (Figure 5B) and in in vitro proliferation
type I,  PRKAR1B 0.212 0.039 0.610 experiments, where ER-positive T47D breast cancer cells weretype II,  PRKAR2A 0.023 0.056 0.597
used (Figure 5C). For FRET and ER-reporter assays, we usedtype II,  PRKAR2B 0.113 0.103 0.224
U2OS cells that are easily transfectable, but are not dependent
Association between expression of PKA-pathway related genes and recur-
on estrogen for their growth when transfected with ER (Planas-rence of breast cancers after tamoxifen treatment. The expression of PKA-
Silva et al., 1999). In contrast, growth of ER-positive T47D breastpathway related genes was determined in 70 breast tumors that were
surgically removed prior to tamoxifen treatment. Expression levels were de- cancer cells is estrogen-dependent, and can be inhibited by
termined using a pool of 56 randomly chosen breast tumors from this series anti-estrogens. When T47D cells were transfected with PKA-
as a reference, as indicated in the Experimental Procedures. RIRNAi, however, they continued to proliferate in the presenceaMean log2 value of the gene expression in the nonrecurrent group of
of tamoxifen, but not with ICI 182780. Activation of PKA bybreast cancers.
bMean log2 value of gene expression in the recurrent group of breast can- RNAi for PKA-RI induced protein expression of a progesterone
cers. receptor related protein of 140 kDa that is normally induced by
cp value of Wilcoxon rank sum test between recurrent and nonrecurrent E2 only (data not shown). This suggests that tamoxifen-bound
group of breast cancers. A significant difference is given by a p value 
ER can act as a transcriptional activator, like E2-bound ER,0.05. The gene expression that significantly differed between the nonrecur-
after modification by PKA, as indicated by the transactivationrent and recurrent group is marked in bold.
reporter assays as well (Figure 5B). T47D cells transfected with
an empty vector ceased to proliferate in the presence of these
anti-estrogens (Figure 5C). Elevated PKA activity (by reduction
of PKA-RI) resulted in increased E2-driven proliferation as well,PKA-RI and resistance to tamoxifen
comparable to the increased ER transactivation measured byWe studied the relevance of PKA activation for tamoxifen resis-
ERE luciferase activity under those conditions (Figure 3B), as
tance in 70 ER primary breast cancers that were isolated
has also been reported previously (Chen et al., 1999). Quantita-
before tamoxifen treatment, of which 20 patients showed recur-
tion of colony densities of T47D cells with reduced levels of PKA-
rence of the tumor. These primary tumors were consequently RI as compared to controls indicated that growth in tamoxifen
classified as tamoxifen-resistant. The remaining 50 patients conditions exceeded that in conditions of ICI-182780 or hor-
showed no recurrence in the form of metastasis after an average mone ablation by approximately 2-fold, implying that both
follow-up period of 132 months, which classified these tumors downregulation of PKA-RI and tamoxifen were required for
as potentially tamoxifen-sensitive. However, the nonrecurrent the increased cell growth (Table 2). Evidently, downregulation of
group may have contained tamoxifen-resistant cases that did PKA-RI resulted in activation of the PKA pathway and induced
not show recurrence because of the absence of micrometas- selective tamoxifen resistance not only under experimental con-
tases. The clinical details of the patient groups and the microar- ditions, but also in breast cancer patients. Under these condi-
ray approach used in this study are given in Supplemental Ta- tions, tamoxifen binds to ER, but cannot induce the inhibitory
bles S1 and S2 at http://www.cancercell.org/cgi/content/full/5/ conformation. Even more important, tamoxifen is now activating
6/597/DC1. The expression profile of each tumor was analyzed ER-controlled transcription and tumor cell growth.
using a pool of tumors as a reference. The association of expres-
sion of the different genes within the PKA pathway with tamoxi- Discusssion
fen sensitivity was evaluated by correlation of the average ex-
pression of each gene with the outcome of disease (van ‘t Veer Here we show that PKA activation sufficed to induce tamoxifen
et al., 2002). Only expression of the negative regulatory subunit resistance in breast cancer. In principle, this can be achieved
of PKA, PKA-RI, was found to be significantly reduced in ta- by alteration of one or more steps within the PKA pathway
moxifen-resistant breast tumors, whereas other components of (Figure 6). However, constitutive activation of PKA is difficult
the PKA pathway were not involved (Table 1 and Supplemental to achieve through G protein-coupled receptors or adenylate
Data). Among the 100 genes whose altered expression was cyclase, because these receptors are desensitized after activa-
associated with tamoxifen resistance, no gene involved in the tion. Yet alteration can be achieved by overexpression of PKA
MAP kinase pathway was found to be associated with tamoxifen or downregulation of the inhibitory subunit PKA-RI, of which
the latter occurred in most of the primary breast tumors thatresistance. Also, neither SRC-1 nor cyclin D1 was found to be
CANCER CELL : JUNE 2004 601
A R T I C L E
Figure 5. Reduced expression of the negative
regulatory subunit of PKA, PKA-RI, results in ta-
moxifen resistance and induces breast cancer
growth
A: Reduced expression of PKA-RI by RNAi results
in tamoxifen resistance, but not ICI-182780 resis-
tance. Time course of YFP/CFP ratio of a YFP-
ER-CFP expressing U2OS cell. 107 M 4-OH-tamox-
ifen (TAM) was added in the control experiment
(left panel). Alternatively, cells were cotrans-
fected with PKA-RI-RNAi, which considerably re-
duced expression of PKA-RI, as determined by
Western blot analysis (insert). These cells were
subsequently treated with 107 M 4-OH-tamoxi-
fen (TAM) and 106 M ICI-182780 (ICI) (middle), or
in the reversed order (right panel), as indicated.
B: ER transactivation determined by ERE-lucifer-
ase activity of control U2OS cells transfected with
YFP-ER-CFP alone (RNAi), and cells cotrans-
fected with PKA-RI-RNAi (RNAi). Cells were
cultured in CTS medium or in CTS medium con-
taining 107 M 4-OH-tamoxifen (TAM) for two
days.
C: Reduced expression of PKA-RI by RNAi results
in tamoxifen resistant- but not ICI-182780-resis-
tant proliferation. Electroporation of pSuper-PKA-
RI DNA (1 g) or control empty vector (pSuper)
into 100,000 single T47D cells and subsequent culturing of these in the presence of either CTS medium, 107 M ICI-182780 (ICI), 107 M 4-OH-tamoxifen (TAM),
or 107 M E2 for three weeks resulted in tamoxifen-resistant proliferation. Coomassie blue staining of the resulting colonies is shown.
appear resistant to subsequent tamoxifen treatment (Table 1). fen induced resistance through a unique mechanism; PKA modi-
Obviously, we cannot exclude additional mechanisms for induc- fied the ER such that tamoxifen still bound to but was unable
ing tamoxifen resistance. Our experimental RNAi approach, to convert the receptor into an inactive conformation. As a result,
however, showed that reduction of PKA-RI alone was sufficient tamoxifen activated ER-mediated transcription and now acted
to induce tamoxifen resistance. Downregulation of PKA-RI in as an agonist instead of an antagonist. This modification led to
breast tumor sections has already been associated with tamoxi- a specific tamoxifen-resistant proliferation, whereas sensitivity
fen resistance (Miller et al., 1997), but here we directly implicate to ICI-182780 remained unaltered. The stabilized conformation
this protein as a causative factor in this process and describe the of ER might lead to either enhanced recruitment of cofactors,
mechanism of its action. By combining biophysical techniques such as SRC-1, or to reduced binding of corepressors, such
(FRET) with microarray and RNAi technology, we have impli- as NCor. These factors are subject to modification of PKA them-
cated the PKA pathway in tamoxifen resistance, not only in selves, which may contribute to recruitment/dissemination by/
tissue culture cells, but also in breast cancer patients, and have from ER that is modified by PKA (Wagner et al., 1998). Resis-
identified ER serine-305 as the critical target site. Interestingly, tance to ICI 182780 was only achieved when additional factors,
this site is located near the hinge region of ER. Our FRET such as overexpression of SRC1 and cyclin D1, were involved
findings indicated that tamoxifen is able to bind to a PKA modi- (Figure 3). In that case, it is likely that overexpression of cofactor
fied ER (Figures 4B and 4C). Phosphorylation of serine-305 SRC1 and cyclin D1 helped to stabilize the interaction between
by PKA therefore appears to affect the stability of the conforma- SRC1 and ER, consolidating the PKA-induced conformational
tion of ER upon anti-estrogen binding rather than the binding change in ER even further. This resulted to an active conforma-
properties of the receptor itself. FRET also revealed that tamoxi- tion of ER also in the presence of ICI 182780, as measured
by FRET. It is known that tamoxifen can act both as ER antago-
nist and agonist—antagonistic in breast tissue, while agonistic
in a number of other tissues, such as osteoblasts (O’Regan and
Table 2. Colony density of T47D breast cancer cells transfected with Jordan, 2002). For this reason, tamoxifen has beneficial effects
PKA-RI RNAi pSuper or with pSuper alone and cultured for three
on osteoporosis by stimulating ER-dependent proliferation ofweeks under various hormonal conditions
osteoblasts. Why tamoxifen induces opposite effects in different
T47 D cells transfected with: tissues is unclear. Overexpression of SRC-1 has been claimed
Hormone condition pSuper pSuper PKA-RI ratio to be one factor (Shang and Brown, 2002). However, our data
showed that this did not suffice to convert the antagonisticCTS 0.96 	 0.29 4.46 	 0.68 4.66
effects of tamoxifen into an agonistic effect, unless PKA was10-7M.ICI 182780 0.76 	 0.22 3.46 	 0.11 4.55
10-7M. OH-tamoxifen 1.04 	 0.39 8.58 	 2.04 8.69 activated as well. The activity of PKA may therefore be the
10-7M.E2 10.02 	 0.38 33.78 	 3.01 3.37 critical factor. This is highly relevant for breast cancer patients,
After Coomassie blue staining, the density of the colonies presented in since tamoxifen may induce the opposite effect when PKA is
Figure 5C was measured as described by Brummelkamp et al. (2002), and activated, stimulating ER-dependent tumor growth rather than
is given in arbitrary units. inhibiting it. Indeed, this situation is encountered in the clinic in
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Figure 6. Model for PKA-mediated resistance to tamoxifen
ER-complex binds to its cognate ERE recognition site in the promoter of estrogen responsive genes. Transcription is mediated through the subsequent
recruitment of a number of coactivators, an interaction stabilized by cyclin D1.
A: Nonresistant cells. The binding of tamoxifen (T) to ER prevents the recruitment of coactivator SRC-1 and impedes ER-mediated transcription.
B: Tamoxifen-resistant cells. Activation of PKA prevents tamoxifen-mediated inhibition of ER transactivation. The PKA pathway can be activated by ligand
binding to a G protein-coupled receptor (7TM receptor). G proteins subsequently activate adenylate cyclase that generates cAMP. Adenylate cyclase
activity is stabilized by forskolin. cAMP binding to the catalytic subunit of the PKA complex releases the inhibitory subunit PKA-RI from the PKA complex.
The catalytic PKA subunit (c) now phosphorylates serine-305 of ER and thus blocks conversion into its inactive conformation by tamoxifen. In fact, tamoxifen
now promotes ER induced transcription and proliferation of hormone-dependent breast tumor cells. Reduction in expression of PKA-RI, as observed in
many tamoxifen-resistant breast cancer patients or by RNAi, also results in PKA activation and tamoxifen resistance. Phosphorylation of Ser-305 of ER then
controls the switch from inhibition to growth stimulation by tamoxifen.
2002) and 1 ng of SV40 Renilla luciferase construct, and cells were incubatedthe “withdrawal response,” where tamoxifen-resistant breast
under the conditions indicated for 48 hr. The luciferase assay was performedtumor ceases to grow upon withdrawal of tamoxifen (Canney
as described (Bindels et al., 2002).et al., 1987). This counterintuitive effect of tamoxifen can be
understood from our observations where tamoxifen is converted
Fluorescence resonance energy transfer (FRET)
from an inhibitor into a growth stimulator when the estrogen For FRET experiments, cells on coverslips were placed on an inverted Zeiss
receptor  is phosphorylated at position 305 by PKA. Patients Axiovert 135 microscope equipped with a dry Achroplan 63 objective.
who are potentially resistant to tamoxifen should be identified FRET equipment was as described previously (van der Wal et al., 2001).
CFP was excited at 432 	 5 nm and emission of YFP was detected at 527and treated with unequivocal ER antagonists such as ICI-
nm and CFP at 478 nm. FRET was expressed as ratio of YFP to CFP signals.182780 (Fulvestrant). Indeed, 45% of the tamoxifen-resistant
The ratio was arbitrarily set as 1.0 at the onset of the experiment. Changesbreast cancer patients respond favorably to treatment with Ful-
are expressed as percent deviation from this initial value of 1.0. For datavestrant (Howell et al., 2002).
acquisition, Felix software (PTI Inc.) was used.
Experimental procedures
YFP-ER-CFP constructs and in vitro phosphorylation
The pCMV-ER construct was obtained from P. Chambon (Strasbourg). ACell culture, transfection, and ERE-luciferase reporter assays
fusion construct was made by ligation of PCR products from ER and CFPU2OS and T47D cells were cultured in DMEM medium in the presence of
in-frame in the YFP-PH pcDNA3 vector (van der Wal et al., 2001). We used10% FCS and standard antibiotics. U2OS cells containing ER constructs
primer 5
CCCAGAATCAATGACCCTCCACACCAAAGCATCT, creating anwere cultured in phenol red-free DMEM medium containing 5% charcoal
EcoRI site, and 5
CCCACTCGAGGAC TGTGGCAGGGAAACCCTCT, elimi-treated serum (CTS, Hyclone). For the FRET experiments, cells were cultured
nating the stop codon of ER, and introduced a XhoI site compatible withon 2 cm round glass coverslips, and at the times indicated estradiol (Sigma),
the 5
 SalI site from CFP (sequence 5
CCCAGTCGACATGGTGAGCAAGGG4-OH-tamoxifen (Sigma), or ICI-182780 (Tocris) was added at the concentra-
CGAGGA), while a stop codon was introduced at the 3
end (5
CCCATCTAtions indicated. Forskolin (Sigma) was added 15 min prior to measurements
GATC ACTTGTACAGCTCGTCCATG). The single fluorescent protein con-at a final concentration of 105 M. For the ERE-luciferase experiments, 107
taining ER constructs (YFP-ER and ER-CFP) was constructed in anM estrogen or anti-estrogen was added to the medium after transfection,
identical manner. Site-directed mutagenesis of serine-236 and -305 to ala-followed by culturing the cells for 48 hr before harvesting. For transient
nine was performed with the CFP-ER-YFP construct as a template usingtransfections, 4  105 U2OS cells were plated in a 6-well plate culture dish
the appropriate modified oligonucleotides. All constructs were verified byand cultured overnight. The cells were transfected with 1 g of expression
sequence analysis. The pcDNA3-YFP-ER-CFP construct was transfectedvectors pCMV-cyclin D1, pCMV-SRC-1 (Zwijsen et al., 1998), and 0.4 g
in U2OS cells, and after 48 hr, cells were inspected by confocal microscopyof pcDNA3-YFP-ER-CFP (see below) using Transfast reagents (Promega)
for YFP emission at 500–565 nm. Protein expression was examined byfollowing the manufacturer’s protocol. For ERE-luciferase reporter assays,
cells were transfected with 1 g ERE-Tk-Firefly luciferase (Bindels et al., Western blotting using antibodies against ER- (Stressgen Biotechnologies
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Corp) and GFP (van Ham et al., 1997) and detected using an ECL detection made using the Wilcoxon rank sum test, based on the magnitude of the
kit (Amersham). correlation coefficient (van ‘t Veer et al., 2002). After Monte Carlo analysis,
The in vitro protein kinase A assay was performed as described before a cutoff point of a correlation of 0.37 was chosen. Some 100 genes appeared
(Yang et al., 1996). Briefly, equal amounts of protein of wt and Ser 236 or to have a higher correlation and were thus strongly associated with recur-
-305 mutants of immunopurified YFP-ER-CFP were incubated with 10 units rence. PKA-RI was one of these genes with a high correlation (rank order
of bovine protein kinase A catalytic subunit (Sigma) and 32P-ATP for 30 min 53), and was shown by a two-sample t test to be significantly downregulated
at 30C, under conditions provided by the supplier. Half of the reaction was in the group with recurrence compared to the group without recurrences
evaluated by autoradiography after SDS-PAGE gelelectrophoresis, the other (two-sample t test for combined probes; p value  0.0000697). The other
half by Western blotting using antibody against GFP. genes of the PKA pathway included in the array did not show a significant
difference between the recurrence and nonrecurrence group (p value 
pSUPER-PKA-RI construct and in vitro proliferation 0.05). All data for the relevant probes is shown in Supplemental Table S2.
To generate the pSUPER-PKA-RI, the RNAi vector pSUPER (Brummelkamp
et al., 2002) was digested with BglII and HindIII and the annealed oligos Acknowledgments
containing the sequence GGGGATAACTTCTATGTGA specific for PKA-RI
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